이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

파킨슨병 환자를 대상으로 한 번타네탑 연구

2026년 10월 28일 업데이트: Annovis Bio Inc.

파킨슨병 환자를 대상으로 Buntanetap의 장기 안전성을 조사하는 개방형 임상시험

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

연구 유형

중재적

등록 (추정된)

500

단계

  • 2 단계
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • 모병
        • University of Alabama at Birmingham
        • 연락하다:
        • 수석 연구원:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, 미국, 85351
        • 모병
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • 수석 연구원:
          • Sara Dhanani, M.D.
        • 연락하다:
    • California
      • Fountain Valley, California, 미국, 92708
        • 모병
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • 수석 연구원:
          • Daniel Truong, M.D.
        • 연락하다:
          • Evan Moreno-Davis
          • 전화번호: 714-378-5074
          • 이메일: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, 미국, 80113
        • 모병
        • Cenexel Rocky Mountain Clinical Research
        • 연락하다:
        • 수석 연구원:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, 미국, 06824
        • 모병
        • New England Institute for Clinical Research (Ki Health Partners)
        • 연락하다:
        • 수석 연구원:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, 미국, 33180
        • 모병
        • First Choice Neurology - Aventura Neurologic Associates
        • 수석 연구원:
          • Jonathan Cross, M.D.
        • 연락하다:
      • Daytona Beach, Florida, 미국, 32117
        • 모병
        • Arrow Clinical Trials
        • 연락하다:
        • 수석 연구원:
          • David Billmeier, M.D.
      • DeLand, Florida, 미국, 32720
        • 모병
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • 수석 연구원:
          • Bruce Rankin, D.O.
        • 연락하다:
      • Miami, Florida, 미국, 33172
      • Miami, Florida, 미국, 33015
        • 아직 모집하지 않음
        • Ezy Medical Research Co.
        • 연락하다:
      • Ocala, Florida, 미국, 34470
        • 모병
        • Renstar Medical Research
        • 수석 연구원:
          • Annette Nieves, M.D.
        • 연락하다:
      • Tampa, Florida, 미국, 33613
        • 모병
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • 연락하다:
        • 수석 연구원:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, 미국, 32789
    • Georgia
      • Decatur, Georgia, 미국, 30030
        • 모병
        • iResearch Atlanta
        • 연락하다:
        • 수석 연구원:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, 미국, 46256
        • 모병
        • Josephson Wallack Munshower Neurology, P.C.
        • 수석 연구원:
          • Kristi George, M.D.
        • 연락하다:
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • 모병
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • 연락하다:
        • 수석 연구원:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, 미국, 48334
        • 모병
        • Quest Research Institute
        • 수석 연구원:
          • Aaron Ellenbogen, D.O.
        • 연락하다:
    • New York
      • New York, New York, 미국, 10019
        • 모병
        • Mount Sinai Hospital
        • 수석 연구원:
          • Joohi Jimenez-Shahed, M.D.
        • 연락하다:
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • 모병
        • Duke Department of Neurosurgery
        • 수석 연구원:
          • Kyle Mitchell, M.D.
        • 연락하다:
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • 모병
        • The Ohio State University Wexner Medical Center
        • 수석 연구원:
          • Zachary Jordan, M.D.
        • 연락하다:
    • Oklahoma
      • Tulsa, Oklahoma, 미국, 74136
        • 모병
        • The Movement Disorder Clinic of Oklahoma
        • 연락하다:
        • 수석 연구원:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, 미국, 19090
        • 모병
        • Abington Neurology
        • 수석 연구원:
          • David Weisman, M.D.
        • 연락하다:
    • South Carolina
      • Charleston, South Carolina, 미국, 29401
        • 모병
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • 연락하다:
        • 수석 연구원:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, 미국, 38018
        • 모병
        • Neurology Clinic, P.C.
        • 연락하다:
        • 수석 연구원:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, 미국, 38157
        • 모병
        • Veracity Neuroscience LLC
        • 연락하다:
        • 수석 연구원:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, 미국, 78681
        • 모병
        • Central Texas Neurology
        • 연락하다:
        • 수석 연구원:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, 미국, 22903
        • 모병
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • 수석 연구원:
          • Binit Shah, M.D.
        • 연락하다:
    • Washington
      • Spokane, Washington, 미국, 99202
        • 모병
        • Inland Northwest Research
        • 수석 연구원:
          • Jason Aldred, M.D.
        • 연락하다:
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • 모병
        • Medical College of Wisconsin
        • 연락하다:
        • 수석 연구원:
          • Karen Blindauer, M.D.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

실험적: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Safety of buntanetap
기간: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
기간: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
기간: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
기간: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Laurie Sanders, Ph.D., Duke Clinical Research Institute

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 9일

기본 완료 (추정된)

2029년 9월 1일

연구 완료 (추정된)

2029년 11월 1일

연구 등록 날짜

최초 제출

2025년 11월 26일

QC 기준을 충족하는 최초 제출

2025년 12월 9일

처음 게시됨 (실제)

2025년 12월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 28일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ANVS-25002

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .